Close

Share this page

For customers outside of Japan

Locations

Since 2013 EPS has established a solid foundation in Asia to provide superior clinical research infrastructure for development of pharmaceuticals and medical devices. From Japan to China to India and throughout Southeast Asia, our network connects you to trends and the way to work effectively in the largest and most dynamic markets in the world.


Which country are you interested in? Click on the country to find out more.


Hong Kong
Jun. 22, 2017
Hong Kong: an attractive alternative to China for clinical trials

Complex rules and regulations can make conducting trials in mainland China a challenge. This is despite the fact its pharmaceutical market is the second largest ...

Hong Kong
Jun. 22, 2017
Hong Kong's new efficiencies in regulatory approvals for clinical trials

In order to ensure the quality of clinical trials conducted in Hong Kong, it is mandatory to apply for a certificate before conducting any clinical trials in Hong Kong ...

India
Jun. 22, 2017
India's regulatory reforms for clinical trials

Due to low costs and a large patient population, India was previously considered a top-tier location for clinical trials. However, India's limited infrastructure and less-efficient ...

India
Jun. 22, 2017
The role of the Clinical Trials Registry – India (CTRI)

The Clinical Trials Registry - India (CTRI) is hosted at the National Institute of Medical Statistics in the Indian Council of Medical Research. Launched in July 2007, the CTRI is a FREE online ...

Singapore
Jun. 22, 2017
Singapore: Asia's hub for biotechnology and clinical research

Over the last 20 years, Singapore has successfully established a solid foundation for scientific innovation. As part of a national strategy to become the Asian hub ...

Australia
Mar. 31, 2017
Phase 1 clinical trial opportunities: Australia shows the world it's open for business

Clinical trial opportunities are booming in Australia as companies around the world look for new ways to secure reliable data and get ahead of their competitors ...

Australia
Mar. 31, 2017
For global cancer clinical trials, Australia is a premium location

Cancer Australia, an Australian government agency, estimated new cancer cases diagnosed in 2016 at 130,466. Cancer Australia also estimated the number of ...

China
Mar. 31, 2017
Clinical trials in China: the potential and pitfalls

Clinical trials are a global industry, but many companies are reconsidering where they will conduct their work in the future. One of the most promising locations is China ...

China
Mar. 31, 2017
Post-marketing surveillance in China: what it reveals

With a population of over 1.3 billion people and an annual increase of approximately 16 million people, China requires 500 million vaccine doses each year ...

Philippines
Mar. 31, 2017
Clinical trial regulations in the Philippines: application and protocol approval

Clinical trial regulations in the Philippines are now of the utmost importance. The amount of clinical trials conducted has increased substantially over the years ...

Philippines
Mar. 31, 2017
Neglected tropical diseases and rabies: the struggles of the Philippine government

The Philippines has long been plagued by neglected tropical diseases (NTDs) such as schistosomiasis, soil-transmitted helminthiasis, leptospirosis, dengue and rabies ...

Japan
Oct. 3, 2016
The SMO plays a critical role in Japan’s clinical trials landscape

Japan’s clinical environment differs in many respects from other countries. Even within Asia, there are important differences between Japan and its closest neighbors ...

Japan
Oct. 3, 2016
Navigating Japan’s medtech regulatory environment

Japan is the world’s third largest healthcare market behind the United States and China. Its health insurance is well financed and coverage is effectively universal. Its teaching hospitals ...

South Korea
Oct. 3, 2016
Korea is rapidly becoming a regional leader in clinical trials

Although a latecomer to clinical research, CRO activity in South Korea has grown rapidly since its origin in 1995. Particularly, since 2007, with the establishment of Korean ...

South Korea
Oct. 3, 2016
Vigorous investment in drug development and biosimilars in Korea are creating a global powerhouse

Strategic investment and targeted policy is transforming Korea's pharmaceutical industry, as it moves away from generics towards biosimilars ...

Taiwan
Oct. 3, 2016
Merged research promotion body NRBP creates streamlined vehicle for encouraging research

The National Research Program for Biopharmaceuticals (NRBP) was formed in 2011 from the merger of two national research promotional bodies in ...

Taiwan
Oct. 3, 2016
Entering the Chinese market has just become easier as cross-strait cooperation bears fruit

Taiwan's strategic focus on biotechnology, its GCP-compliant professionals, global outlook and widely respected FDA, are some of the ...


We will tailor an ideal solution for your specific needs.

Contact Us